ExpressCells and Funakoshi Establishes Japanese Distribution Agreement
Partnership will Introduce ExpressCells' Genetically-Edited Cell Lines to Japan
By: ExpressCells, Inc.
The agreement brings together two companies advancing innovation by supporting the needs of the Japanese biological research community. By genetically editing cell lines, ExpressCells allows researchers to conduct better experiments and expand biological knowledge. Funakoshi enhances the ability of scientists to achieve solutions by providing a wide range of scientific tools and materials.
"We are honored that Funakoshi, a highly-respected company with a long history of extending the frontiers in life science, will distribute our catalog cell lines and identify customers who can benefit from our custom cell lines," said Matt Handel, CEO of ExpressCells. "We look forward to providing the highest quality cell lines to the Japanese research community."
ExpressCells uses its proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other types of biological research. The speed of the process allows ExpressCells to insert one to three genes into the same cell line months faster than other technologies. ExpressCells sells both custom and catalog cell lines. For more information, visit xpresscells.com or email Matt Handel at firstname.lastname@example.org.
Funakoshi Co., Ltd. has contributed as a leader to distribute research reagents and instruments for researchers in the life science fields since its foundation. Its corporate mission is to provide high quality products to broad range of customers throughout a domestic and international network. To learn more and to view the product brochure, visit www.funakoshi.co.jp. For more information on Funakoshi, please contact Tetsuya Ikeda at +813-5684-1611 or email@example.com.